Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer

Dis Markers. 2003-2004;19(4-5):185-95. doi: 10.1155/2004/546293.

Abstract

Multiple studies have reported that analysis of serum and other bodily fluids using surface enhanced laser desorption/ionization time of flight mass spectroscopy (SELDI-TOF-MS) can identify a "fingerprint" or "signature" of spectral peaks that can separate patients with a specific disease from normal control patients. Ultimately, classification by SELDI-TOF-MS relies on spectral differences in position and amplitude of resolved peaks. Since the reproducibility of quantitation, resolution and mass accuracy of the SELDI-TOF-MS, or any high throughput mass spectrometric technique, has never been determined this method has come under some skepticism as to its clinical usefulness. This manuscript describes a detailed design of a three-phase study to validate the clinical usefulness of SELDI-TOF-MS in the identification of patients with prostatic adenocarcinoma (PCA). At the end of this validation study, the usefulness of the general SELDI-TOF-MS approach to identifying patients with PCA will be demonstrated and how it compares with PCA diagnosis by measuring prostate specific antigen.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / diagnosis*
  • Algorithms
  • Blood Proteins / analysis*
  • Clinical Trials as Topic
  • Humans
  • Male
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Research Design
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Substances

  • Blood Proteins